Press release content from Business Wire. The AP news staff was not involved in its creation.
BeiGene Presents Clinical Data on Sitravatinib in Combination with Tislelizumab at the AACR Annual Meeting 2021
April 11, 2021 GMT
CAMBRIDGE, Mass. & BEIJING (BUSINESS WIRE) Apr 11, 2021
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative medicines worldwide, today announced that clinical data on its anti-PD-1 antibody tislelizumab, in combination with the investigational spectrum-selective kinase inhibitor sitravatinib being jointly developed with Mirati Therapeutics, Inc. (Mirati), were presented in two oral presentations at the American Association for Cancer Research (AACR) Annual Meeting 2021. Data presented at the meeting were from two cohorts of a Phase 1b trial (NCT03666143), in patients with unresectable or metastatic melanoma who were refractory or resistant to PD-1/L1 inhibitors and in patien
Nearly a quarter of patients who received Opdivo plus chemotherapy showed no evidence of cancer cells in tissue removed during surgery vs. 2.2% of patients who received chemotherapy alone Opdivo- based therapies have now demonstrated positive results in Phase 3 trials in earlier stages of four different types of cancer: non-small cell lung cancer, esophagealgastroesophageal junction cancer, bladder cancer and … Nearly a quarter of patients who received Opdivo plus chemotherapy showed no evidence of cancer cells in tissue removed during surgery vs. 2.2% of patients who received chemotherapy alone Opdivo- based therapies have now demonstrated positive results in Phase 3 trials in earlier stages of four different types of cancer: non-small cell lung cancer, esophageal/gastroesophageal junction cancer, bladder cancer and melanoma
Blueprint Medicines Presents Preclinical Data Highlighting Broad Precision Therapy Research Pipeline at AACR Annual Meeting 2021 Preclinical data presented at AACR highlight four precision therapies with first- or best-in-class potential IND application cleared by FDA for BLU-945, a triple-mutant EGFR inhibitor for EGFR-driven lung cancer Nominated BLU-222, a selective and potent CDK2 inhibitor development candidate, for cyclin E-aberrant cancers Blueprint Medicines to host investor conference call and webcast on Monday, April 12 at 8:00 a.m. ET
News provided by
Share this article
Share this article
CAMBRIDGE, Mass., April 10, 2021 /PRNewswire/ Blueprint Medicines Corporation (NASDAQ: BPMC) today announced data from multiple poster presentations highlighting the breadth of the company s precision therapy pipeline at the virtual American Association for Cancer Research (AACR) Annual Meeting 2021. Collectively, the presentations, including foundational preclin
Date Time
Study of mouse gut microbiome may provide clues to how cancer develops in humans
A study of the mouse gut microbiome led by researchers from Mayo Clinic may shed light on how cancerous tumors develop and progress in humans. The findings will be presented this evening in a late-breaking abstract (#LB226) at the 2021 American Association for Cancer Research annual meeting.
“There is growing recognition that healthy tissues accumulate cancer-related mutations over time but they don’t necessarily cause illness,” says stem cell and cancer biologist Nagarajan Kannan, Ph.D., who led the study. “We asked the question, what would trigger these aberrant cells to grow uncontrollably and develop into a malignancy?”
Fusion Pharmaceuticals Announces Preclinical Combination Data Demonstrating Enhanced Efficacy in Multiple Preclinical Tumor Models
News provided by
Share this article
Share this article
Product candidate FPI-1434, when administered with olaparib, resulted in enhanced efficacy against colorectal and lung cancer xenografts
Combination of IGF-1R targeted alpha therapy with immune checkpoint inhibitors demonstrated enhanced efficacy in colorectal cancer models
Data featured in e-poster sessions at the 2021 AACR Virtual Annual Meeting
HAMILTON, ON and BOSTON, April 10, 2021 /PRNewswire/ Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced the presentation of preclinical data at the 2021 American Association for Cancer Research (AACR) Virtual Annual Meeting. The posters will be presented during the Preclinical Radiotherapeutics and Combination Immunotherap